Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy

Falavarjani, Khalil Ghasemi; Hashemi, Masih; Modarres, Mehdi; Ali, Khaleda

doi:10.1038/eye.2014.21

Cited by 36 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…95 A prospective trial of patients with PVR grade C undergoing vitrectomy with silicone oil (SiO) placement randomized patients to receive intravitreal bevacizumab 1.25mg at the conclusion of the case, and the results showed no difference in visual acuity, redetachment rate, and PVR recurrence between the groups receiving and not receiving bevacizumab at 7 months. 96 Similar results were observed in a patients with PVR grade B or better. 97…”

Section: Introductionsupporting

confidence: 77%

Proliferative Vitreoretinopathy: A Review

Idrees

Sridhar

Kuriyan

2019

International Ophthalmology Clinics

180

169

View full text Add to dashboard Cite

Proliferative vitreoretinopathy (PVR) is the most common cause for failure of rhegmatogenous retinal detachment repair and is characterized by the growth and contraction of cellular membranes within the vitreous cavity and on both sides of the retinal surface as well as intraretinal fibrosis. Currently, PVR is thought to be an abnormal wound healing response that is primarily driven by inflammatory, retinal, and RPE cells. At this time, surgery is the only management option for PVR as there is no proven pharmacologic agent for the treatment or prevention of PVR. Laboratory research to better understand PVR pathophysiology and clinical trials of various agents to prevent PVR formation are ongoing.

show abstract

Section: Introductionsupporting

confidence: 77%

Proliferative Vitreoretinopathy: A Review

Idrees

Sridhar

Kuriyan

2019

International Ophthalmology Clinics

180

169

View full text Add to dashboard Cite

show abstract

“…8 With these promising results, a recent study of 38 patients with RRD and preoperative PVR evaluated the role of a bevacizumab injection into silicone oil at the end of surgery. 23 Unfortunately, retinal redetachment rates were not statistically different between the treatment and control groups. Also, subretinal fibrous proliferation and preretinal membranes occurred more in the treated group (55.5% vs. 14.3%).…”

Section: Growth Factor Signalingmentioning

confidence: 88%

Pharmacotherapies for Retinal Detachment

2016

View full text Add to dashboard Cite

Retinal detachment is an important cause of visual loss. Currently, surgical techniques, including vitrectomy, scleral buckle, and pneumatic retinopexy, are the only means to repair retinal detachment and restore vision. However, surgical failure rates may be as high as 20%, and visual outcomes continue to vary secondary to multiple processes, including postoperative cystoid macular edema, epiretinal membrane formation, macular folds, and, ultimately, photoreceptor death. Therefore, pharmacotherapies are being sought to aid the success rates of modern surgical techniques and reduce or slow the degeneration of photoreceptors during retinal detachment. This review discusses potential therapeutic avenues that aid in retinal reattachment, reduce the rate of retinal redetachment by limiting proliferative vitreoretinopathy, and protect against photoreceptor cell death.

show abstract

“…Similarly, work has been done to evaluate the ability of anti-vascular endothelial growth factors (anti-VEGF) to prevent PVR. Experiments with Bevacizumab have shown no superiority in functional outcomes, re-detachment rates, and PVR formation between trial and control groups across various grades of PVR [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Use of Intravitreal Methotrexate Infusion in Complicated Retinal Detachment for Prevention of Proliferative Vitreoretinopathy in a Pilot Study

Jahangir¹,

Jahangir²,

Ali³

et al. 2021

Cureus

View full text Add to dashboard Cite

Objective The objective of this pilot study was to evaluate the efficacy and safety of per-operative intravitreal methotrexate (MTX) infusion during vitrectomy in patients of retinal detachment (RD) with advanced grade proliferative vitreoretinopathy (PVR). Methods In this prospective interventional case series, we included patients with Grade C PVR, recurrent RD, and open globe trauma. All patients underwent standard single surgeon operated 23-gauge pars plana vitrectomy (PPV) with 80mg of MTX in 1000mL of irrigation fluid. All patients were followed up after four months to assess the final status of retinal attachment and visual acuity. Ethical review board permission was sought for this off-label use of MTX and all patients signed an informed consent form before this intervention. Results Thirty eyes of 30 patients with recurrent retinal detachment, open globe trauma, or grade C PVR at initial presentation were included in this study. After PPV, these patients were followed up after four months. A total of 24 (80%) patients maintained retinal attachment at four months. Mean preoperative best-corrected visual acuity (BCVA) was 1.35 logarithm of the minimum angle of resolution (logMAR) (range 0.5-3) and mean four months postoperative BCVA was 1.01 logMAR (range 0.3-3) (Student’s t -test; P -value <0.05). Seventeen (56.6%) eyes had pre-operative BCVA of 1.0 whereas 25 (83.3%) had BCVA of 1.0 at the end of the follow-up period. Six (20%) patients had preoperative BCVA of 0.7 whereas 12 (40%) patients had BCVA of 0.7 at four months postoperatively. Out of six (20%) eyes developing RD after this intervention, four eyes achieved retinal reattachment after a second surgery. We did not observe any MTX-related complications during the follow-up period of this study. Conclusion Intravitreal MTX infusion during PPV for complicated RD as an adjunctive therapy showed encouraging results and was found to be safe in its use. We need more rigorous and controlled studies to confirm the possible advantages of MTX and its role in the prevention of PVR.

show abstract

Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy

Cited by 36 publications

References 34 publications

Proliferative Vitreoretinopathy: A Review

Proliferative Vitreoretinopathy: A Review

Pharmacotherapies for Retinal Detachment

Use of Intravitreal Methotrexate Infusion in Complicated Retinal Detachment for Prevention of Proliferative Vitreoretinopathy in a Pilot Study

Contact Info

Product

Resources

About